Hackensack Meridian John Theurer Cancer Center | Strategic Alliance Partners

Latest from Hackensack Meridian John Theurer Cancer Center

Study Shows Sleep Disturbances During the Pandemic Were Similar between Breast Cancer Survivors and Healthy Controls

May 19, 2022

Results from the Thinking and Living with Cancer Study showed that the development of sleep disturbances during the early months of the COVID-19 pandemic increased symptoms of depression and anxiety among older women, but the findings did not differ between women who survived breast cancer and women without cancer.

John Theurer Cancer Center Investigators Confirm that Preserved Stem Cells Are Safe and Effective for Multiple Myeloma Treatment Up to 20 Years Later

April 21, 2022

Investigators from Hackensack University Medical Center’s John Theurer Cancer Center confirm that cryopreserved stem cells collected before a first stem cell transplant to treat multiple myeloma are just as viable and potent for use in a second "salvage" transplant 20 years later.

Oral Decitabine Plus Cedazuridine Combo Shows Promise in Lower-Risk MDS

January 12, 2022

James K. McCloskey, MD, discusses the efficacy of oral decitabine plus cedazuridine, the combination’s potential role in lower-risk myelodysplastic syndromes, and what this could mean for the patient population.

Dr. Goy on the Utility of Axi-Cel and Brexu-Cel in Relapsed/Refractory Non-Hodgkin Lymphoma

January 10, 2022

Andre H. Goy, MD, discusses the clinical data reported with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma and real-world findings with brexucabtagene autoleucel in mantle cell lymphoma.